Skip to main navigation
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications & Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Stories
    • Patient Stories
    • Disease Focus
      • Overview
      • Transthyretin Amyloidosis
      • Hereditary Angioedema
      • Alpha-1 Antitrypsin Deficiency
      • Hodgkin Lymphoma
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications &
      Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Focus
    • Patient Stories
    • Disease Focus
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events &
      Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

Investors & Media

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Stock Information

  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Mar 21, 2023
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
Read More
Events & Presentations
More events are coming soon.
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.